A detailed history of Securian Asset Management, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Securian Asset Management, Inc holds 97,693 shares of ABBV stock, worth $16.6 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
97,693
Previous 101,538 3.79%
Holding current value
$16.6 Million
Previous $17.4 Million 10.78%
% of portfolio
0.56%
Previous 0.51%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $629,964 - $766,423
-3,845 Reduced 3.79%
97,693 $19.3 Million
Q2 2024

Jul 15, 2024

SELL
$154.79 - $180.76 $379,390 - $443,042
-2,451 Reduced 2.36%
101,538 $17.4 Million
Q1 2024

Apr 26, 2024

SELL
$159.82 - $182.1 $1.25 Million - $1.42 Million
-7,801 Reduced 6.98%
103,989 $18.9 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $2.05 Million - $2.3 Million
-14,873 Reduced 11.74%
111,790 $17.3 Million
Q3 2023

Oct 30, 2023

SELL
$133.59 - $154.65 $2.86 Million - $3.31 Million
-21,396 Reduced 14.45%
126,663 $18.9 Million
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $273,765 - $340,683
-2,066 Reduced 1.38%
148,059 $19.9 Million
Q1 2023

Apr 27, 2023

BUY
$144.61 - $166.54 $89,658 - $103,254
620 Added 0.41%
150,125 $23.9 Million
Q4 2022

Feb 02, 2023

BUY
$138.31 - $165.87 $296,951 - $356,122
2,147 Added 1.46%
149,505 $24.2 Million
Q3 2022

Oct 28, 2022

BUY
$134.21 - $153.93 $95,557 - $109,598
712 Added 0.49%
147,358 $19.8 Million
Q2 2022

Aug 04, 2022

SELL
$137.62 - $174.96 $127,848 - $162,537
-929 Reduced 0.63%
146,646 $22.5 Million
Q1 2022

May 03, 2022

SELL
$131.98 - $163.75 $266,071 - $330,120
-2,016 Reduced 1.35%
147,575 $23.9 Million
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $220,661 - $279,200
-2,054 Reduced 1.35%
149,591 $20.3 Million
Q3 2021

Nov 08, 2021

SELL
$106.4 - $120.78 $173,857 - $197,354
-1,634 Reduced 1.07%
151,645 $16.4 Million
Q2 2021

Aug 10, 2021

SELL
$105.21 - $117.21 $93,636 - $104,316
-890 Reduced 0.58%
153,279 $17.3 Million
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $509,658 - $561,072
-4,982 Reduced 3.13%
154,169 $16.7 Million
Q4 2020

Feb 08, 2021

SELL
$80.49 - $108.67 $248,472 - $335,464
-3,087 Reduced 1.9%
159,151 $17.1 Million
Q3 2020

Nov 04, 2020

SELL
$85.91 - $100.83 $151,717 - $178,065
-1,766 Reduced 1.08%
162,238 $14.2 Million
Q2 2020

Aug 06, 2020

BUY
$73.37 - $98.18 $1.29 Million - $1.73 Million
17,607 Added 12.03%
164,004 $16.1 Million
Q1 2020

May 07, 2020

SELL
$64.5 - $97.79 $153,445 - $232,642
-2,379 Reduced 1.6%
146,397 $11.2 Million
Q4 2019

Feb 04, 2020

SELL
$72.13 - $90.25 $297,536 - $372,281
-4,125 Reduced 2.7%
148,776 $13.2 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $79,354 - $95,407
-1,260 Reduced 0.82%
152,901 $11.6 Million
Q2 2019

Aug 05, 2019

BUY
$65.7 - $83.98 $101,572 - $129,833
1,546 Added 1.01%
154,161 $11.2 Million
Q1 2019

Apr 26, 2019

SELL
$77.14 - $90.79 $131,369 - $154,615
-1,703 Reduced 1.1%
152,615 $12.3 Million
Q4 2018

Feb 04, 2019

SELL
$77.85 - $96.01 $126,272 - $155,728
-1,622 Reduced 1.04%
154,318 $14.2 Million
Q3 2018

Oct 26, 2018

SELL
$88.91 - $98.84 $10,135 - $11,267
-114 Reduced 0.07%
155,940 $14.7 Million
Q2 2018

Aug 09, 2018

SELL
$89.78 - $106.23 $672,901 - $796,193
-7,495 Reduced 4.58%
156,054 $14.5 Million
Q1 2018

Apr 30, 2018

SELL
$92.01 - $123.21 $30,271 - $40,536
-329 Reduced 0.2%
163,549 $15.5 Million
Q4 2017

Feb 05, 2018

BUY
$89.56 - $98.21 $178,403 - $195,634
1,992 Added 1.23%
163,878 $15.8 Million
Q3 2017

Nov 03, 2017

BUY
$69.85 - $89.22 $90,036 - $115,004
1,289 Added 0.8%
161,886 $14.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
160,597
160,597 $11.6 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $300B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Securian Asset Management, Inc Portfolio

Follow Securian Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Securian Asset Management, Inc with notifications on news.